Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.
News|Articles|April 19, 2025
Top 5 Infectious Disease New Stories Week of April 18-April 25
Author(s)Sophia Abene
This week, the CDC ACIP's endorsement of meningococcal, RSV, and chikungunya vaccines, the need to expand automated CD4 testing for improved HIV/AIDS care, and more.
Advertisement
Advertisement
MeMed CEO Eran Eden, PhD, discusses the MeMed BV test, a rapid diagnostic tool that distinguishes between bacterial and viral infections in just 15 minutes, aiding clinical decision-making and antibiotic stewardship. The blood test, which analyzes three host-response proteins and generates a score to assess bacterial infection likelihood, has received FDA 510(k) clearance and the European CE Mark. Clinical studies showed a 63% reduction in unnecessary antibiotic use, accurate identification of previously missed bacterial infections, and better performance than traditional biomarkers like procalcitonin. Eden highlights the test’s ability to address diagnostic gaps, such as inaccessible infections, pathogen colonization, and superinfections, and reduce uncertainty that often leads to antibiotic misuse. By improving diagnostic accuracy, the MeMed BV test contributes to safer patient care and helps combat antimicrobial resistance.
Related to this article
Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Advertisement
Advertisement